A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05155709
- Locations
- 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇹🇷Novartis Investigative Site, Izmir, Turkey
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16246
- Registration Number
- NCT05157087
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05156281
- Locations
- 🇺🇸
Neurocare Plus, Houston, Texas, United States
🇺🇸Ctr for Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Vladimir Royter MD APMC, Hanford, California, United States
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
- Conditions
- Non-radiographic Axial SpondyloarthritisModerate to Severe Plaque PsoriasisAnkylosing SpondylitisPsoriatic Arthritis
- Interventions
- Other: secukinumab
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT05155098
- Locations
- 🇹🇭
Novartis Investigative Site, Nakhon Ratchasima, Thailand
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4320
- Registration Number
- NCT05153135
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05147220
- Locations
- 🇺🇸
US Associates in Research, Miami, Florida, United States
🇺🇸AZ Integrated Neuro and Spine, Phoenix, Arizona, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Other: AfliberceptOther: BevacizumabOther: Ranibizumab
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 369600
- Registration Number
- NCT05146687
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4650
- Registration Number
- NCT05141240
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
Impact of Fingolimod Adherence on Outcomes
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 694
- Registration Number
- NCT05141669
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Other: CarboplatinOther: Etoposide
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05142696
- Locations
- 🇺🇸
Georgetown University Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸University Cancer and Blood Center LLC, Athens, Georgia, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States